Home Media/Press releases/OREGA announces licensing of CD39 Program to Innate Pharma>
Latest News
See all news

Media

Press release

OREGA announces licensing of CD39 Program to Innate Pharma

 

Press Release

 

Lyon, France, January 10th, 2016

 

OREGA Biotech announces Licensing Agreement with Innate Pharma

 

OREGA Biotech today announces that it has entered into an exclusive licensing agreement with Innate Pharma by which OREGA grants Innate full worldwide rights to its program of first-in-class anti-CD39 immune checkpoint inhibitors. This license agreement arose from a fruitful research collaboration between the two companies initiated in 2014. Under the terms of the agreement, OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales.

 

For more information, read the press release (English version / Version française)

 

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. With a specific focus on tumor microenvironment, OREGA’s Target Discovery Program aims at discovering and validating novel clinically-relevant cancer targets.

Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. OREGA’s business strategy is to bring its R&D programs up to preclinical proof of concept, IND or early clinical stages and then to license them out to larger biotech or pharmaceutical companies. Funded by initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative, the company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.

For more information: www.orega-biotech.com  

 

Contact

Jeremy Bastid, Chief Operating Officer

Tel.: +33 (0)4 37 49 87 20

jeremy.bastid@orega-biotech.com

 


See all our press releases

Events
See all events